Urinary markers of altered collagen metabolism in fibromyalgia patients

References

• Sprott H., Muller A., Heine H. Collagen crosslinks in fibromyalgia. Arthritis Rheum 1997; 40: 314–7
   Google Scholar
• Appelboom T., Schoutens A. High bone turnover in fibromyalgia. Calcif Tissue Int 1990; 46: 314–7
   PubMed Web of Science ®Google Scholar
• Jacobsen S., Gam A., Egsmose C., Olsen M., Danneskiold‐Samsoe B., Jensen G. F. Bone mass and turnover in fibromyalgia. J Rheumatol 1993; 20: 856–9
   PubMed Web of Science ®Google Scholar
• Jacobsen S., Jensen L. T., Foldager M., Danneskiold‐Samsoe B. Primary fibromyalgia: clinical parameters in relation to serum procollagen type III aminoterminal peptide. Br J Rheumatol 1990; 29: 174–7
   PubMedGoogle Scholar
• Gronemann S. T., Ribel‐Madsen S., Bartels E. M., Danneskiold‐Samsoe B., Bliddal H. Collagen and muscle pathology in fibromyalgia patients. Rheumatology (Oxford) 2004; 43: 27–31
   PubMed Web of Science ®Google Scholar
• Ribel‐Madsen S., Gronemann S. T., Bartels E. M., Danneskiold‐Samsoe B., Bliddal H. Collagen structure in skin from fibromyalgia patients. Int J Tissue React 2005; 27: 75–82
   PubMedGoogle Scholar
• Mense S. [Neurobiological basis of muscle pain]. Schmerz 1999; 13: 3–17. German
   PubMedGoogle Scholar
• Wolfe F., Smythe H. A., Yunus M. B., Bennett R. M., Bombardier C., Goldenberg D. L., et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160–72
   PubMed Web of Science ®Google Scholar
• Burckhardt C. S., Clark S. R., Bennett R. M. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991; 18: 728–33
   PubMed Web of Science ®Google Scholar
• Cloos P. A. C., Fledelius C., Christgau S., Christiansen C., Engsig M., Delmas P., et al. Investigation of bone disease using isomerized and racemized fragments of type I collagen. Calcif Tissue Int 2003; 72: 8–17
   PubMedGoogle Scholar
• Christgau S., Garnero P., Fledelius C., Moniz C., Ensig M., Gineyts E., et al. Collagen type II C‐telopeptide fragments as an index of cartilage degradation. Bone 2001; 29: 209–15
   PubMed Web of Science ®Google Scholar
• Mouritzen U., Christgau S., Lehmann H. J., Tanko L. B., Christiansen C. Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index. Ann Rheum Dis 2003; 62: 332–6
   PubMed Web of Science ®Google Scholar
• Colwell A., Russell R. G. G., Eastell R. Factors affecting the assay of urinary 3‐hydroxy pyridinium crosslinks of collagen as markers of bone resorption. Eur J Clin Invest 1993; 23: 341–9
   PubMed Web of Science ®Google Scholar
• Kivirikko K. I., Laitinen O., Prockop D. J. Modifications of a specific assay for hydroxyproline in urine. Anal Biochem 1967; 19: 249–55
   PubMed Web of Science ®Google Scholar
• Mazess R. B., Barden H., Ettinger M., Schultz E. Bone density of the radius, spine, and proximal femur in osteoporosis. J Bone Miner Res 1988; 3: 13–8
   PubMed Web of Science ®Google Scholar
• American College of Sports Medicine; ACMSs Guidelines for Exercise Testing and Prescription, A Kaminsky, Leonard. Lippincott Williams & Wilkins, Baltimore 1995, 5th edition
   Google Scholar
• Reginster J. Y., Henrotin Y., Christiansen C., Gamwell‐Henriksen E., Bruyere O., Collette J., et al. Bone resorption in post‐menopausal women with normal and low BMD assessed with biochemical markers specific for telopeptide derived degradation products of collagen type I. Calcif Tissue Int 2001; 69: 130–7
   PubMed Web of Science ®Google Scholar
• Müller A., Jakob K., Hein G. E. Evaluation of free and peptide bound collagen crosslink excretion in different skeletal diseases. Ann Rheum Dis 2003; 62: 65–7
   PubMedGoogle Scholar
• Bernardi D., Zaninotto M., Plebani M. Requirements for improving quality in the measurement of bone markers. Clin Chim Acta 2004; 346: 79–86
   PubMedGoogle Scholar
• Garnero P., Gineyts E., Christgau S., Finck B., Delmas P. D. Association of baseline levels of urinary glucosyl‐galactosyl‐pyridinoline and type II collagen C‐telopeptide with progression of joint destruction in patients with early rheumatoid arthritis. Arthritis Rheum 2002; 46: 21–30
   PubMedGoogle Scholar
• Garnero P., Conrozier T., Christgau S., Mathieu P., Delmas P. D., Vignon E. Urinary type II collagen C‐telopeptide levels are increased in patients with rapidly destructive hip osteoarthritis. Ann Rheum Dis 2003; 62: 939–43
   PubMed Web of Science ®Google Scholar
• Jung M., Christgau S., Lukoschek M., Henriksen D., Richter W. Increased urinary concentration of collagen type II C‐telopeptide fragments in patients with osteoarthritis. Pathobiology 2004; 71: 70–6
   PubMed Web of Science ®Google Scholar
• Christgau S., Bitsch‐Jensen O., Bjarnason N. H., Henriksen E. G., Qvist P., Alexandersen P., Henriksen D. B. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 2000; 26: 505–11
   PubMed Web of Science ®Google Scholar
• Rovetta G., Monteforte P., Grignolo M. C., Brignone A., Buffrini L. Hematic levels of type I collagen C‐telopeptide in erosive versus nonerosive osteoarthritis of the hands. Int J Tissue React 2003; 25: 25–8
   PubMedGoogle Scholar
• Eyre D. New biomarkers of bone resorption. J Clin Endocrinol Metab 1992; 74: 470A–C
   PubMed Web of Science ®Google Scholar
• Takahashi M., Hoshino H., Kushida K., Inoue T. Direct measurement of crosslinks, pyridinoline, deoxypyridinoline, and pentosidine, in the hydrolysate of tissues using high‐performance liquid chromatography. Anal Biochem 1995; 232: 158–62
   PubMed Web of Science ®Google Scholar
• Seibel M. J., Gartenberg F., Silverberg S. J., Ratcliffe A., Robins S. P., Bilezikian J. P. Urinary hydroxypyridinium cross‐links of collagen in primary hyperparathyroidism. J Clin Endocrinol Metab 1992; 74: 481–6
   PubMed Web of Science ®Google Scholar
• Lueken S. A., Arnaud S. B., Taylor A. K., Baylink D. J. Changes in markers of bone formation and resorption in a bed rest model of weightlessness. J Bone Miner Res 1993; 8: 1433–8
   PubMed Web of Science ®Google Scholar
• Seibel M. J., Duncan A., Robins S. P. Urinary hydroxy‐pyridinium crosslinks provide indices of cartilage and bone involvement in arthritic diseases. J Rheumatol 1989; 16: 964–70
   PubMed Web of Science ®Google Scholar
• Sinigaglia L., Varenna M., Binelli L., Bartucci F., Arrigoni M., Ferrara R., et al. Urinary and synovial pyridinium crosslink concentrations in patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 1995; 54: 144–7
   PubMedGoogle Scholar
• Rüster M., Franke S., Späth M., Pongratz D. E., Stein G., Hein G. E. Detection of elevated N epsilon‐carboxymethyllysine levels in muscular tissue and in serum of patients with fibromyalgia. Scand J Rheumatol 2005; 34: 460–3
   PubMed Web of Science ®Google Scholar
• Borderie D., Roux C., Toussaint B., Dougados M., Ekindjian O. G., Cherruau B. Variability in urinary excretion of bone resorption markers: limitations of a single determination in clinical practice. Clin Biochem 2001; 34: 571–7
   PubMedGoogle Scholar